Dicerna Pharmaceuticals downgraded by Goldman Sachs with a new price target
$DRNA
Major Pharmaceuticals
Health Care
Goldman Sachs downgraded Dicerna Pharmaceuticals from Buy to Neutral and set a new price target of $25.00 from $36.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/9/2021 | $28.00 → $38.25 | Buy → Neutral | Chardan Capital |
| 11/19/2021 | $30.00 → $38.25 | Outperform → Sector Perform | RBC Capital |
| 11/18/2021 | $32.00 → $38.25 | Buy → Neutral | HC Wainwright & Co. |
| 8/11/2021 | $36.00 → $25.00 | Buy → Neutral | Goldman Sachs |
| 8/10/2021 | $34.00 → $28.00 | Buy | Chardan Capital |
| 8/10/2021 | $38.00 → $32.00 | Buy | HC Wainwright & Co. |
| 8/9/2021 | $32.00 | Buy → Neutral | Citigroup |
| 8/6/2021 | $35.00 → $30.00 | Outperform | RBC Capital |